The role of Epstein-Barr virus in NK/T cell lymphoproliferative disorders: molecular mechanisms and potential therapeutic strategies
By
Ming Fan
Haiming Kou
Liang V. Tang
July 14, 2026
Clinical Scorecard: Investigating the Impact of Epstein-Barr Virus on NK/T Cell Lymphoproliferative Disorders: Insights into Molecular Mechanisms and Possible Treatment Approaches
At a Glance
Category Detail
Condition Epstein-Barr Virus-related T/NK Cell Lymphoproliferative Disorders Key Mechanisms Viral biological properties, regulation of latent and lytic cycles, immune evasion, and host signaling pathways (NF-κB, PI3K-AKT, JAK-STAT). Target Population Individuals with EBV infection, particularly those at risk for T/NK cell lymphoproliferative disorders. Care Setting Clinical oncology and hematology.
Key Highlights
EBV can lead to a range of lymphoproliferative disorders, particularly aggressive T/NK cell types. Molecular mechanisms include viral protein functions and host signaling pathway activation. Novel therapeutic strategies such as PD-1/PD-L1 inhibitors and EBV-specific T cell therapy are being developed. High-sensitivity detection methods may improve classification of EBV-related diseases. Guideline-Based Recommendations
Diagnosis
Use conventional EBER in situ hybridization and quantitative PCR for EBV detection. Management
Consider targeted therapies like immune checkpoint inhibitors and T cell therapy. Monitoring & Follow-up
Monitor viral load using quantitative PCR and other high-sensitivity methods. Risks
EBV-related T/NK cell disorders can progress to aggressive lymphomas and leukemias. Patient & Prescribing Data
Patients with EBV-positive T/NK cell lymphoproliferative disorders.
Personalized medicine approaches and multimodal decision-making are recommended for treatment.
Clinical Best Practices
Integrate viral taxonomy and detection methodology in clinical assessments. Recognize the heterogeneity of EBV latency patterns in T/NK cell disorders. Related Resources & Content
